Enanta Pharmaceuticals, Inc.
ENTA
$13.02
$0.221.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.42% | -9.94% | -11.55% | -9.55% | -14.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.42% | -9.94% | -11.55% | -9.55% | -14.61% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -3.42% | -9.94% | -11.55% | -9.55% | -14.61% |
| SG&A Expenses | -24.06% | -17.34% | -10.21% | -4.46% | 9.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.42% | -17.04% | -20.02% | -17.97% | -12.52% |
| Operating Income | 29.86% | 21.20% | 24.58% | 22.33% | 11.31% |
| Income Before Tax | 29.07% | 20.36% | 23.87% | 21.72% | 10.08% |
| Income Tax Expenses | 4.76% | 26.34% | -235.76% | -168.83% | -161.79% |
| Earnings from Continuing Operations | 29.43% | 20.22% | 26.81% | 24.10% | 13.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.43% | 20.22% | 26.81% | 24.10% | 13.28% |
| EBIT | 29.86% | 21.20% | 24.58% | 22.33% | 11.31% |
| EBITDA | 32.33% | 22.69% | 25.50% | 22.79% | 11.48% |
| EPS Basic | 30.03% | 20.82% | 27.32% | 24.58% | 13.92% |
| Normalized Basic EPS | 29.95% | 22.19% | 25.45% | 23.25% | 12.18% |
| EPS Diluted | 30.03% | 20.82% | 27.32% | 24.58% | 13.92% |
| Normalized Diluted EPS | 29.95% | 22.19% | 25.45% | 23.25% | 12.18% |
| Average Basic Shares Outstanding | 0.86% | 0.79% | 0.71% | 0.64% | 0.79% |
| Average Diluted Shares Outstanding | 0.86% | 0.79% | 0.71% | 0.64% | 0.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |